ASCO 2026 Preview: 10 Tickers to Watch
- 16 hours ago
- 4 min read
Updated: 2 hours ago
ASCO is one of the most important weeks of the year for biotech investors. Clinical updates presented during the meeting can rapidly reshape company narratives, regulatory expectations, partnership interest, and valuation outlooks, especially for small and mid-cap oncology companies.
Using BPIQ MCP, we screened for companies where ASCO 2026 presentations could represent meaningful inflection points. The final list includes pivotal Phase 3 datasets, late-stage regulatory setups, high-volatility microcaps, and companies where a single presentation may heavily influence the rest of 2026!
$IDYA (IDEAYA Biosciences)
$IDYA enters ASCO with one of the most important late-stage datasets in uveal melanoma. The company will present late-breaking pivotal OptimUM-02 Phase 2/3 data for darovasertib + crizotinib in metastatic uveal melanoma in an oral session on June 1. The trial has already met its primary PFS endpoint (n=435), and the program is advancing under FDA RTOR review, with filing completion targeted for H2 2026.
Why it matters: If the data confirm durability and efficacy expectations, this could become the first broadly usable systemic therapy in uveal melanoma. With IDEAYA still largely driven by this single lead program (cap ~$2.6B), ASCO could materially impact both regulatory confidence and valuation trajectory.
$KPTI (Karyopharm Therapeutics)
$KPTI is presenting pivotal SENTRY Phase 3 data evaluating selinexor + ruxolitinib in first-line myelofibrosis, in an oral session on June 2, with FDA sNDA engagement already planned.
Why it matters: Karyopharm remains one of the more heavily shorted oncology small caps, with short interest near 35% of float (BPIQ) and a market cap of roughly $200M, while already carrying a commercial XPO1 product. A positive SENTRY outcome could reshape the company narrative, reopen sNDA discussions, and, given current positioning, drive a high-volatility reaction.
$RVMD (Revolution Medicines)
$RVMD may host the single biggest ASCO event this year, with plenary data for daraxonrasib (RMC-6236) in frontline pancreatic cancer (RASolute 302) on May 31. The topline is already known to be positive, with both PFS and OS met; the program carries Breakthrough Therapy designation and a CNPV, with an NDA planned for H2 2026.
Why it matters: The topline result is known. What investors now want is depth: overall survival magnitude, durability, and combination details. With Revolution's valuation heavily tied to the broader RAS(ON) platform thesis, the quality of the plenary details could significantly influence sentiment across the entire pipeline.
$COGT (Cogent Biosciences)
$COGT will present full pivotal PEAK data for bezuclastinib + sunitinib in second-line GIST in an oral session on May 30. PEAK reported a 16.5-month median PFS and 46% ORR, and the NDA is already under RTOR review with a PDUFA date of November 30, 2026.
Why it matters: ASCO could further de-risk the commercial launch opportunity in GIST while reinforcing confidence in Cogent's broader mastocytosis franchise. Investors will likely focus on efficacy consistency, tolerability, and competitive positioning within KIT-driven tumors.
$BDTX (Black Diamond Therapeutics)
$BDTX is presenting oral Phase 2 data for silevertinib (BDTX-1535) in frontline non-classical EGFR-mutant NSCLC on May 30. Early efficacy metrics have already attracted attention, including a 15.2-month median PFS and strong CNS activity at 86% CNS ORR, with full duration-of-response and PFS detail due at the meeting.
Why it matters: For a nano-cap company (roughly $130M) built primarily around a single asset, deeper progression-free survival and duration-of-response data may heavily influence investor confidence. CNS penetration remains a major strategic focus in EGFR lung cancer, making this one of the more technically important datasets among smaller caps.
$IMRX (Immuneering)
$IMRX will report updated Phase 2a data for atebimetinib (IMM-1-104) in frontline pancreatic cancer in an oral session on June 1, expanding to the full N=55 dataset after an interim that showed a 17.3-month median OS.
Why it matters: That earlier interim survival data surprised many investors in one of oncology's hardest settings. The key question at ASCO is whether the signal holds as patient numbers expand. For a micro cap (roughly $345M) centered around this lead asset, confirmation could substantially increase visibility around the program.
$IMNM (Immunome)
$IMNM is presenting registration-enabling RINGSIDE Phase 3 data for varegacestat in desmoid tumors in an oral session on May 30. The trial met its primary and key secondary endpoints, with a reported hazard ratio of 0.16 and 56% ORR.
Why it matters: The reported hazard ratio and response rate already suggest potentially differentiated efficacy. ASCO gives investors a chance to evaluate the full dataset quality as the company moves toward filing discussions. With varegacestat acting as a major value driver (cap ~$2.5B), execution matters here.
$AGEN (Agenus)
$AGEN will present updated data for botensilimab + balstilimab in anti-PD-1 refractory cutaneous melanoma (C-800-23) as a poster on May 31, with a reported 16.6-month median OS.
Why it matters: Agenus remains a micro cap (roughly $140M) where the botensilimab franchise represents the core strategic asset. Investors will focus closely on survival durability and whether the dataset supports broader immuno-oncology relevance beyond melanoma.
$CRDF (Cardiff Oncology)
$CRDF is presenting updated CRDF-004 Phase 2 data for onvansertib combined with chemotherapy and bevacizumab in metastatic colorectal cancer on June 2, with an investor webcast to follow on June 3. The company has already completed its FDA End-of-Phase-2 meeting, with Phase 3 details expected mid-2026.
Why it matters: That makes ASCO a critical setup event before Phase 3 design clarity. For a micro cap near $124M, updated efficacy trends may heavily influence confidence in the pivotal path forward.
$AAPG (Ascentage Pharma)
$AAPG enters ASCO with three olverembatinib (HQP1351) presentations across leukemia and GIST: second-line CML-CP showing 91.3% CCyR and 60.9% MMR at cycle 24 (rapid oral, May 30), a Ph+ ALL POLARIS-1 update (May 30), and SDH-deficient GIST data of 23.1% PR and 25.7-month PFS (poster, June 1).
Why it matters: Unlike many small oncology names relying on a single readout, Ascentage brings multiple shots on goal into the meeting. Strong hematology efficacy metrics combined with a cash position that exceeds its market cap (roughly $2.5B versus $2.0B) may create a more asymmetric setup compared with many similarly sized biotech companies.
The 10 names above are a curated slice of the ASCO 2026 calendar. The BPIQ catalyst calendar tracks every upcoming readout, PDUFA, and major medical conference across biopharma, in one place, updated daily, so you can spot the next move before it moves.
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
Updated 05/29/26 RF First published 05/28/26 MD, RF